Drospirenone/estetrol - Mithra Pharmaceuticals

Drug Profile

Drospirenone/estetrol - Mithra Pharmaceuticals

Alternative Names: DRSP/E4; E4/DRSP; Estelle; Estetrol/Drospirenone; FSN-013

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Estetra S.A.
  • Developer Estetra S.A.; Fuji Pharmaceutical
  • Class Androstenes; Anti-inflammatories; Antiandrogens; Antimigraines; Antineoplastics; Gonadal steroid hormones; Hormonal replacements; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Estrogen receptor beta modulators; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pregnancy

Most Recent Events

  • 10 Oct 2018 Mithra files for patent protection for drospirenone/estetrol
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Pregnancy(Prevention) in Bulgaria (PO, Tablet)
  • 24 Sep 2018 Drospirenone/estetrol licensed to Hyundai Pharm in South Korea for commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top